Paul Matteis
Recent Articles about Alto Neuroscience Inc.
Buy Rating Reaffirmed: ALTO-207 TRD Trial on Track 03/25/2026
Stifel reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE) after an in-line Q4 2025 earnings report.
© 2026 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
